LIFE PHARMA-DETOX PROJECT
Demonstration of an innovative method for the detoxification of pharmaceutical wastewater from pharmaceutical facilities. This project aims to the development and implementation of an innovative, economically viable and cost-efficient system for the transformation of pharmaceutical compounds, present in wastewater, into non-toxic substances. In this way, the environmental impacts occurring due to poor controlled discharge of APIs in the wastewater sewage system will be eliminated.
Latest News
The European Commission has adopted the 5th update of the Watch List — a list of substances suspected of posing risks to both environmental and human health through aquatic exposure. The revised list includes 12 substances, ranging from plant protection products and antibiotics to human pharmaceuticals and a tyre rubber antioxidant. EU Member State experts...
The 78th World Health Assembly (WHA78), held in Geneva from 19 to 27 May 2025, placed a spotlight on antimicrobial resistance (AMR) as a critical threat to global health and sustainable development. During the Assembly, Member States endorsed the update of the Global Action Plan on AMR, reaffirming their commitment to combat one of the...
Tests to optimise operation of RO pilot plant continue by the NTUA and Medochemie researchers, at the LIFE Pharma Detox pilot unit in Cyprus. The operation of the RO unit has started and the results are very promising! The difference of turbidity between inlet and permeate stream is shown in the picture.
LIFE PHARMA-DETOX
The project is co-funded by LIFE
The project is co-funded by LIFE, the EU’s financial instrument supporting environmental, nature conservation and climate action projects throughout the EU.
Our Project is also part of the LIFE projects that are co-Funded by the Green Fund. The project team would like to thank the Green Fund for co-funding the NTUA activities. More specifically, according to the Decision Number 242.4/2022 of the Management Board of the Green Fund, the amount of 60,000 Euro was approved for the year 2022.